Kidney Stones in Primary Hyperoxaluria: New Lessons Learnt

Dorrit E. Jacob1,*, Bernd Grohe2, Michaela Geßner3, Bodo B. Beck4, Bernd Hoppe5

1 Department of Geosciences, Johannes Gutenberg University Mainz, Mainz, Germany, 2 Schullich School of Medicine and Dentistry, School of Dentistry, Western University, London, Canada, 3 Division of Pediatric Nephrology, Department of Pediatric and Adolescent Medicine, University Hospital Cologne, Cologne, Germany, 4 Institute of Human Genetics, University of Cologne, Cologne, Germany, 5 Division of Pediatric Nephrology & German Hyperoxaluria Center, Department of Pediatrics, University Hospital Bonn, Bonn, Germany

Abstract

To investigate potential differences in stone composition with regard to the type of Primary Hyperoxaluria (PH), and in relation to the patient’s medical therapy (treatment naive patients versus those on preventive medication) we examined twelve kidney stones from ten PH I and six stones from four PH III patients. Unfortunately, no PH II stones were available for analysis. The study on this set of stones indicates a more diverse composition of PH stones than previously reported and a potential dynamic response of morphology and composition of calculi to treatment with crystallization inhibitors (citrate, magnesium) in PH I. Stones formed by PH I patients under treatment are more compact and consist predominantly of calcium-oxalate monohydrate (COM, whewellite), while calcium-oxalate dihydrate (COD, weddellite) is only rarely present. In contrast, the single stone available from a treatment naive PH I patient as well as stones from PH III patients prior to and under treatment with alkali citrate contained a wide size range of aggregated COD crystals. No significant effects of the treatment were noted in PH III stones. In disagreement with findings from previous studies, stones from patients with primary hyperoxaluria did not exclusively consist of COM. Progressive replacement of COD by small COM crystals could be caused by prolonged stone growth and residence times in the urinary tract, eventually resulting in complete replacement of calcium-oxalate dihydrate by the monohydrate form. The noted difference to the naive PH I stone may reflect a reduced growth rate in response to treatment. This pilot study highlights the importance of detailed stone diagnostics and could be of therapeutic relevance in calcium-oxalates urolithiasis, provided that the effects of treatment can be reproduced in subsequent larger studies.

Introduction

The primary hyperoxalurias (PH I, II and III) are rare, but underdiagnosed autosomal-recessively inherited disorders of the glyoxylate metabolism [1,2]. Recurring urolithiasis and/or progressive nephrocalcinosis (the latter not yet observed in PH III) usually occurring early in childhood are their clinical hallmarks [1–4]. Among the three subtypes PH I is the most prevalent and most disastrous form [1–5]. Although rare (estimated prevalence rate <3 per 10^6 population [6–12] with higher rates reported from some inbred populations [13,14]), PH I regularly causes end-stage renal disease (ESRD) and curative treatment requires combined liver and/or pre-emptive liver transplantation [15]. Even in industrialized countries there is a high rate of late diagnosis in advanced renal failure or after kidney graft failure in the setting of isolated kidney transplantation (up to 40% in adults), which denotes underreporting [6–10]. Infantile oxalosis occurring with generalized nephrocalcinosis and ESRD within the first 3 years of life constitutes the most severe PH I subgroup (up to 20% of cases) and still poses a major therapeutic challenge [1,2,16].

Despite marked hyperoxaluria in the primary range no case of ESRD has been reported yet for PH III [3–5]. It is still unclear, why there is such rate of high clinical remission over time, although hyperoxaluria and hypercalcium seem to persist. Current conservative management in PH is mainly identical to that in idiopathic calcium-oxalate (CaOx) stone disease and is based on a high fluid intake (>2 l per m² body surface area per day) combined with medication to increase the urinary solubility index (alkaline citrate, oralphosphate and/or magnesium [1,2,15,17]). The only specific drug available to PH I patients is pyridoxine (vitamin B6), the natural cofactor of the defective alanine-glyoxylate aminotransferase enzyme (AGT). Given in supraphysiological doses, vitamin B6, a pharmacoperoer for susceptible AGXT missense mutations (e.g. c.508G>A), acts in multiple ways [18], finally leading to a reduced rate of endogenous oxalate generation and decreased urinary oxalate excretion [19,20]. In the long run vitamin B6 treatment, even in (potentially)
susceptible PH I genotypes, does not seems sufficient to overcome the deteriorative effects of massive hyperoxaluria [1,15,20,21].

Early definite diagnosis of primary hyperoxaluria, especially for type I, is of utmost importance and mainly relies on genetic testing in industrialized countries today [22]. As the majority of PH patients present with urolithiasis and their stones have been reported to be distinctly different from idiopathic calcium-oxalate (CaOx) stones [23,24], a concrement-based diagnostic approach could be extremely useful as a general screening tool in urolithiasis, particularly in countries with lower economic resources.

Based on descriptions of stones from PH patients by Daudon et al. [23,24], who reported numerous differences between idiopathic CaOx stones and those of PH patients (mainly PH I), we are exploring here stone characteristics in relation to the precise PH type and genotype in greater detail using light and scanning electron microscopy as well as Micro-Raman spectrometry on surfaces and polished cross-sections. Twelve stones from ten patients diagnosed with PH I and six stones from four patients diagnosed with PH III could be obtained for the study (Table 1). Unfortunately, no stones form PH type II (GRHPR deficiency), the least common PH subtype in Germany [4] were available for analysis. In addition, we tried to differentiate between stones from naive newly-diagnosed and therefore untreated patients (one patient diagnosed with PH I (1 stone) and one with a PH III diagnosis (2 stones, marked with an asterisk in Table 1) and stones formed under treatment with citrate and/or vitamin B6.

Materials and Methods

Ethics Statement

The ethics statement for this study is IRB vote 06-231 (“Genotype-phenotype correlation for patients with primary hyperoxaluria”) obtained through the Ethics Commission of the University Hospital Cologne. The ethics committee specifically approved this study. All patients gave their written informed consent to the study and the ethics committee approved of this procedure.

Patients

In all patients repeated 24 h urine analysis showed severe hyperoxaluria in the primary range (>1.0 mmol/1.73 m²/d), together with an elevated excretion of glycolate (PH I), or calcium (PH III). Diagnosis of PH I and PH III was established by complete PH I-II (AGXT, GRHPR and HOGA1) sequencing in all study participants and subsequent identification of two causative AGXT (PH I), respectively HOGA1 (PH III) mutations (Table 1).

Sample Preparation and Light-Microscopy

Images of stone fragments were taken using a MZ125 binocular microscope (Leica, Wetzlar, Germany, 40× magnification) equipped with a Canon digital camera. Selected fragments were embedded in epoxy resin (Struers, Willich, Germany) then polished in several steps using 800 and 1200 grit Al₂O₃ powder followed by a last polishing step with 1 µm Al₂O₃ powder on a Buehler G-cloth. Light microscopy investigations and digital imaging of the polished surfaces were carried out with a VHX-600 digital microscope (KEYENCE, Neu-Isernb erg, Germany), equipped with a VH-Z25 zoom lens (magnification from 25× to 175×) using polarized light.

Scanning Electron Microscopy (SEM), Energy Dispersive X-ray Analysis (EDX)

A LEO (1540XB, Carl Zeiss, Jena, Germany) scanning electron microscope equipped with a Gemini field emission column was employed to determine compactness of stone masses, surface structure and habit (shape, dimensions, assembly) of formed aggregates and crystal phases and the surface structure of stone matrices. Stone fragments were coated with osmium (~ 4 nm thickness; Plasma Coater OPC-801F) and investigated using an acceleration voltage of 1 kV and a working distance between 3 and 5 mm. The chemical composition of stones was analyzed in several different spots of each sample using EDX (Oxford INCA Instruments) at an acceleration voltage of 20 kV (penetration depth ~2 µm). At least three randomly chosen spots in surface regions and in regions within a stone fragment were analyzed, respectively. Evaluation of the inorganic and organic content of the stones was accomplished by determining the fractions (in wt.%) of calcium phosphate and calcium oxalate minerals (via the stoichiometry of octacalcium phosphate (OCP) and whewellite (COM)/wedellite (COD)), followed by calculation of the organic fraction (based on carbon, oxygen and – less frequently – sulfur). Other elements, such as Na, Cl, K, Al, Zn, Mg were considered as trace compounds (e.g. NaCl, KCl, Al and Zn oxides). As the stones were coated with Os for SEM the Os-content was subtracted before calculating stone compositions.

Micro-Raman Spectrometry

Raman spectra were recorded on polished surfaces of embedded samples using a Horiba Jobin Yvon LabRAM HR (High Resolution) 800 spectrometer equipped with a Si-based CCD-detector (Pelletier-cooled), an integrated Olympus BX41 optical microscope and an automated x-y-stage at University of Mainz. Measurements were carried out with 50× long distance objective (numerical aperture 0.55) and a slit width of 100 µm, choosing laser spot sizes of ca. 2×2 µm. The excitation source was a Helium-Neon laser operated at 632.82 nm. The Rayleigh radiation was blocked using two edge filters and the scattered light was dispersed by a grating with 1800 grooves/mm. Spectra were calibrated using the 520.5 cm⁻¹ hand of a silicon wafer before starting measurements. All spectra were recorded twice. The wavenumber accuracy was ±0.5 cm⁻¹ at a measured spectral resolution of 0.6 cm⁻¹ (Full Width at Half Maximum of the Rayleigh-line).

Results

Calculi from patients with primary hyperoxaluria have a significantly different appearance from idiopathic CaOx stones [23,24]. While the latter are dense and strongly pigmented calculi (Fig. 1E, F), the majority of PH stones have a light surface colour (Fig. 1A–D) and most consist of loose aggregations of differently sized crystals. Augmenting deductions from the current literature, we found that PH I and especially PH III stones are not always uniform in appearance and composition. In addition to the loose crystal aggregations, reportedly typical for PH stones, a number of calculi contained compact areas that display smooth surfaces with fine-grained growth laminations (Fig. 1C). These areas were identified as calcium oxalate monohydrate (COM; Fig. 1C) by micro-confocal Raman spectrometry. The aggregated portions of stones contain calcium oxalate dihydrate (COD) as the major component (e.g. Fig. 1C, arrow), in which the COD crystals displayed the typical bipyramidal crystal-shape (Fig. 2A, B). Calcium Oxalate Monohydrate (COM) was also present, but only as a minor phase.

Relating the stone compositions and morphologies to genetic (PH type) and clinical data showed that stones consisting partly or completely of aggregated COD were from (i) the single PH I individual who had not yet received treatment (Fig. 1A, Table 1)
Table 1. Synopsis of stones used in this study with details of preventive treatment and genotype.

| Sample | PH subtype | Gender, age (yr) | Stone Composition | Age at first symptom/age at diagnosis | Past/Current clinical symptoms | Urinary Calcium excretion (mg/kg/d) | Urinary oxalate excretion (mmol/1.73 m²/d) | Plasma oxalate (µmol/l) | Treatment at time of stone extraction, length (yrs) | Genotype |
|--------|------------|------------------|-------------------|--------------------------------------|-------------------------------|-----------------------------------|------------------------------------------|------------------------|--------------------------------------------------|----------|
| H1     | PH I       | M, 21            | COM               | 2/5                                  | Recurrent UL/None             | 1.04/3.05                        | 2.56/0.63                               | 13.24                  | Citrate+B6 (p.resp.) (16)                         | c.508G>A/c.958delCA |
| H2     | PH I       | M, 15            | COM               | 1/7                                  | Recurrent UL/None             | 4.83/0.83                        | 2.32/1.37                               | 8.43                   | Citrate+B6 (responsive) (9)                      | c.454T>A/c.1151T>C  |
| H3, H5 | PH I       | M, 21, M, 21     | COM, COM          | 4/12                                 | Recurrent UL/Post staghorn calculus, mal-compliance | 1.6/1.09                         | 1.08/0.92                               | 16.69                  | Citrate+B6 (responsive) (9)                      | c.508G>A/c.846+1G>T |
| H6     | PH I       | M, 12            | COM               | 3/5                                  | Recurrent UL/Post transurethral stone removal, intermittent unexpl. hypercalciuria | 0.95/5.05                        | 1.61/2.46                               | 10.68                  | Citrate+B6 (9)                                  | c.481G>A/c.976DelG |
| H9     | PH I       | F, 18            | COM               | 3/12                                 | Recurrent UL/None             | 1.8/1.75                         | 1.76/1.48                               | 11.14                  | Citrate+B6 (responsive) (8)                      | c.508G>A/c.846-3C>G |
| H10    | PH I       | M, 25            | COM               | 1/20 (ESRD)                          | Recurrent UL, mal-compliance/Post combined liver-kidney Tx | 2.12 (post Tx)                   | 5.32 (pre Tx) 0.37 (post Tx)             | 7.48                   | Citrate (post Tx 7 years) Vit B6 (acute post Tx period, respons.) | c.508G>A/c.846-3C>G |
| H18*   | PH I       | M, 23            | COD+COM           | 4/14                                 | Recurrent UL/Acute stone passage in 06/12 | n.d./2.95                        | 1.61/2.14                               | 16.8                   | None, (9)                                       | c.121G>A/c.846+1G>A  |
| H21b,  | PH I       | M, 44            | COD+COM+CAP; COM, | 3/36                                 | Recurrent UL/Systemic Oxalosis, bones, GFR ~ 40 ml/min | 0.6/0.35                        | 2.76/2.92                               | 35.26                  | Citrate+Mg (8)                                  | c.847-1G>C homozygous |
| H21w   |            |                  | CAP               |                                      |                                |                                  |                          |                                      |                                                  |                     |
| H25    | PH I       | F, 16            | COM               | 2/6                                  | Recurrent UL/Last stone episode 05/11 | 0.75/1.19                        | 3.16/1.87                               | 14.46                  | Citrate+B6 (not respons.) (10)                   | c.508G>A homozygous    |
| H27    | PH I       | F, 7             | COM               | 1/3                                  | NC Grade V/NC Grade           | n.d./0.74                        | 1.7/0.61                               | 19.64                  | Citrate+B6 (respons.) (4)                       | c.508G>A homozygous    |
| H4     | PH III     | F, 14            | COD               | 1/13                                 | Recurrent UL in first decade of life/None | 2.29/1.35                        | 1.95/0.88                               | 10.84                  | Citrate(12)                                     | c.221T>G/c.700+5G>T  |
| H7*, H13, H24 | PH III | M, 3          | H7: COD+COM, H13: COD+COM, H24: CAP+COD | 3 months/8 months                  | Recurrent UL in first years of life/Stones in situ, no current stone passage | Ca/Crea ratios 0.5–0.8 mol/mol | 0.8 Ox/Crea ratio up to 3 mol/mol | 17.62                  | None at H7, Citrate (2)                          | c.728C>A homozygous    |
| H11    | PH III     | M, 5             | COD+COM           | 1/1.5                                | Recurrent UL and stone removal during first year of life/Stones in situ, no current stone passage | Ca/Crea 0.42 mol/mol/2.87 | Ox/Crea 1.51 mol/mol/2.87 | 12.26                  | Citrate (3)                                     | c.221T>G/c.700+5G>T  |
| H28*   | PH III     | M, 3             | CAP+COM+COD       | 1.5/1.5                              | UL, stone removal procedure/None | Ca/Crea 0.36/0.78 mol/mol | Ox/Crea 0.449/0.316 mol/mol | n.d.                   | None (1.5)                                      | c.700+5G>T homozygous |

Asterisk denotes stones from newly-diagnosed and at the time untreated patients.

1stone composition determined by multiple spot analyses on one polished surface. UL = Urolithiasis, NC = Nephrocalcinosis, HCT = Hydrochlorothiazide, GFR = Glomerular Filtration Rate, p.resp. = partly responsive to vit. B6 treatment.

doi:10.1371/journal.pone.0070617.t001
and (ii) PH III patients. In the PH III group, a clear discrimination of stone compositions in treated and untreated patients was not possible based on our samples. Here, both groups showed aggregated COD as well as mixtures of aggregated COD and fine-grained COM (Fig. 1C, D).

In contrast, fine-grained stones consisting almost completely of COM were formed by all other nine PH I patients already under treatment with citrate in combination with vitamin B6 or magnesium (Table 1).

A characteristic PH I concrement formed under treatment is shown in cross-section in Fig. 2C. These calculi are more compact, finer-grained and typically consist almost exclusively of COM. These features are also found in idiopathic CaOx stones, but the latter have a very distinct internal structure with an organic-rich core and crystalline mantle (Fig. 1F) and are darker in appearance (Fig. 1E).

All these characteristics are very different from the PH I stones formed under treatment which, although showing some cavities (arrows in Fig. 2C), lack the typical organic-rich core/crystalline mantle structure.

Crystal morphologies of stones from treated PH I patients determined by Scanning Electron Microscopy show densely-
packed aggregates of COM crystals (Fig. 3). These aggregates are composed of individual rosette-like aggregates (Fig. 3A–D, E, H) and sections of stacked crystals (Fig. 3E–H) with randomly distributed and variably-sized cavities between them, corresponding to those seen in the polished stone cross-section in Fig. 2C.

In contrast, stones that contained large amounts of COD, the PH III calculi and the one from the naïve PH I patient exhibit very different crystal morphologies (Fig. 4). Both the outer surface and the internal structure are rough (Fig. 4A, B, D) which is caused by loose aggregation of crystals and heterogeneous crystal size distributions displaying both very large (some as large as 650 μm, see Figs. 4B; 2A, B) and very small (Fig. 4C) bipyramidal COD crystals. In these stones, COM occurs in two different crystal shapes and sizes. Small (<20 μm) doughnut-shaped COM crystals are found in cavities between the large COD crystals (Fig. 4D), while sectioning and polishing of the stones exposed larger (20–150 μm) angular idiomorphic crystals (Fig. 2A, B). COM with this angular crystal habit is always included or intergrown with the COD crystals and is separated from the COD crystals by a small gap.

The surfaces of the large COD crystals facing the outside in this group of stones were found by SEM-EDX analysis to be covered by organic material (possibly composed of a mixture of proteins, tissue fragments, cells etc.), with measured organic concentrations being significantly higher than those within stone fragments (80.86 wt% ±14.04 vs. 10.80 wt% ±4.20). This result contrasts with results for stones from the treatment group which show heterogeneous organic concentrations throughout the stones, but no preferred concentration relative to their morphology (surface: 25.39 wt% ±11.48, inside: 21.32 wt% ±5.43).

Discussion

Effects of Treatment on Stone Composition and Texture

This study examined calcium oxalate composition and morphology in relation to the precise PH type based on mutational testing. Due to the novelty of the PH type III previous studies did
not include this relevant (with regard to numbers and outcome) form and were mainly based on type I disease defined by biochemical analysis.

In addition, we tried to differentiate between calculi formed in naïve patients and those under treatment. For obvious reasons stones from patients with metabolic urolithiasis prior treatment are hard to obtain.

We are aware that our results are currently based on a very small sample number and therefore results have to be interpreted with due caution. The fact that no stones from PH II patients with an intermediate phenotype severity (regarding risk of ESRD) were available for analysis is another limitation.

Although data are limited, we feel that the findings warrant further investigations as they have diagnostic as well as therapeutic implications for the future.

Interestingly, untreated patients with PH I and PH III subtypes form stones containing considerable amounts of COD. This phase forms loose aggregates and displays a large range of crystal sizes in

Figure 3. SEM micrographs of PHI stone fragments from the treatment group. Panels A–D are images of stones (samples H1, H3) showing open structured crystal aggregates. Surfaces (B) of stones and internal structures (C, D) appear to be formed by COM crystals. Panels E–H show surfaces (F) and internal structures (G, H) from more compact PHI stones (samples H6, H9, H10). Scale bars A, E: 400 μm; B, D, F: 40 μm; C: 115 μm; G: 4 μm; H: 100 μm.

doi:10.1371/journal.pone.0070617.g003
These calculi. In COD dominated stones, COM occurs in the interstices as well as in the form of angular crystals included and intergrown with COD. The surprising presence of COD in PH stones somehow contrasts with the findings of Daudon et al. [23], who reported a COM only composition for these stones. However, no precise clinical information with regard to treatment of the patients was given, and at the time precise genotyping of PH-III was not available.

Only one (out of six) PH III stone analysed consisted mainly of COM, but COD was still a minor phase (Fig. 1C). Stones obtained from the PH I treatment group consisted exclusively of stones with compact matrices that were mainly composed of COM crystals with negligible COD content.

For PH III patients in our study group, we detected some increase in COM content upon treatment. However, differences were not significant, based on the fact that (i) the increase in COM content was only small and (ii) the in situ methods chosen for this study do not allow for representative bulk measurements. At present, it cannot be said with confidence whether the absence of a shift to COM stones relates to the different nature of the PH-III subtype since the sample size in this study was still small.

The shift in phase composition of PH I stones formed under treatment to a composition almost exclusively consisting of COM may be likely related to treatment, which aims at inhibition of stone formation and growth. It is well known that citrate and magnesium inhibit nucleation and growth of CaOx stones [25–29]. As COD is stable in pH ranges from 5 to 7.4 [30] citrate and magnesium affect crystallization by direct interaction with the crystallizing matter rather than by increasing its solubility due to the induced change in pH [30,31]. In addition, pyridoxine (vitamin B6) the cofactor for the defective enzyme AGT (PH I), markedly reduces urinary oxalate excretion in susceptible PH I patients [18,19] resulting in an overall effect of lowering or even eliminating CaOx stone formation in response.

Thus, the compositional switch in response to treatment to COM and a dense matrix impregnated with organics forms good evidence for a much reduced growth rate, besides longer residence times of the stones in the urinary tract. COD stones, in contrast, show no incorporation of organics in their matrices, thus pointing to higher growth rates in accordance with literature reports on fast nucleation and growth of COD [32].

Nevertheless, apparently higher growth rates of COD stones do not necessarily correspond to overall short renal tract residence times. Instead, our observations provide evidence for prolonged residence times of the studied COD stones in the patient’s urinary tract from phase transformation of COD to COM as outlined below.

**Phase Transformation of COD to COM**

Many of the large COD crystals show inclusions of, or are intergrown with, small angular COM crystals (Fig. 2A, B). We noted that some of them were nearly completely replaced by aggregates of the small angular COM crystals, while the outer bipyramidal shape of the original large COD crystal was preserved. All of these COM crystals are in contact with COD and all show characteristic gaps between the two phases. The replacement of COD by COM, in parallel with a reduction of grain-size and increase in porosity while the external dimensions and habit of the original phase are preserved are due to a process termed pseudomorphosis which is very widespread in nature (e.g. fossilization, chemical weathering and rock metamorphism). Pseudomorphic mineral replacement is governed by solution-precipitation reactions between mineral phases and a fluid phase and is driven by the thermodynamic stabilities of the minerals involved [33].

Although COD is among the first crystals formed in the urinary tract both of healthy individuals and of stone formers [34], it is a thermodynamically metastable phase and it is well-known that COD subsequently undergoes phase transformation and is replaced by thermodynamically stable COM [35]. Although the exact rates for this transformation in vivo are not known, the rate of transformation is more likely to be relatively slow [36], because the dissolution of COD and precipitation of COM is surface-controlled [37]. Furthermore, numerous different proteins, cell fragments and other organic substances passivize the crystal surfaces [38].

Recent in vitro studies showed that complete transformation is possible in time spans of the order of 5–75 hours [39–41]. This process may easily arrive at complete replacement of the dihydrate by the monohydrate phase in stones in vivo and depends on the residence time in the urinary tract. As the newly-formed COM crystals preserve the shape of the former COD crystal, it is possible to trace this replacement history of the stones with microanalytical methods and to discriminate the calculi in which COD was replaced by COM from those that are original contained COM stones (e.g. PH I treatment group and most idiopathic CaOx stones) [42].
Implications for Formation Mechanisms of PH Stones

If not treated, primary hyperoxaluria results in Ca-Ox stones. Our study implies that stones formed without treatment of the patient with crystallization inhibitors originally contain a considerable fraction of COD, and this phase may even be the dominating phase in these calculi. COD crystals are found in urines of healthy individuals and of stone formers alike [43]. It is envisaged that these crystals nucleate in very large quantities and grow freely-floating in the urinary tract [44] until they reach crystal sizes that block the pathways, promoting further aggregation. Some of the COD crystals are as large as 650 μm (Fig. 2B), a size that could be retained within the child’s kidney and lead way to aggregation as the critical step for calculus formation.

Upon residence in the urinary tract the outside of the aggregated stone receives its organic coating while COD is progressively replaced by COM within the stone (see Fig. 2A, B). This happens until finally, the complete crystal may consist of an aggregation of granular COM crystals that preserve the hypomidal original shape of the replaced COD crystal (a so-called pseudomorph). The finding that a light-coloured CaOx stone consists mainly or even completely of COM pseudomorphs after COD could be an indication for prolonged residence times in the urinary tract. Notably, COM crystals formed via this replacement reaction have a relatively homogeneous grain-size distribution (between 20 and 150 μm), much smaller than their COD hosts. In addition, the newly formed COM aggregates are very brittle because they lack the organic coating of the large COD precursor crystals. This brittleness, for example, causes individual crystals to be lost easily upon sample polishing (exemplified by the many black voids in Figs. 2A, B).

This “downsizing effect” might be beneficial for the natural decomposition of stones and/or for supporting processes by which the smaller and non-adhesive crystals are more easily flushed out with the tubular fluid stream and excreted.

Acknowledgments

The study was part of our current genotype/phenotype study in patients with primary hyperoxaluria, which was approved by the local ethics committee. We are grateful to all patients who participated in this study.

The authors thank Stephan Buhr (Geosciences Dept., Johannes Gutenberg University, Mainz) for skilful polishing of the samples, Todd Simpson (Nanofabrication Facility, Department of Science, Western University) for help with electron microscopy.

Author Contributions

Conceived and designed the experiments: DEJ BG BBB BH. Performed the experiments: DEJ BB MM BG BH. Analyzed the data: DEJ BG BB MG. Contributed reagents/materials/analysis tools: DEJ BB BB BH. Wrote the paper: DEJ BG BH.

References

1. Hoppe B, Beck BB, Milliner DS (2009) The primary hyperoxalurias. Kidney Int 75: 1264–1271.
2. Leumann E, Hoppe B (2001) The primary hyperoxalurias. J Am Soc Nephrol 12: 1986–1993.
3. Belostotsky R, Sebouh I, Helson GH, Milliner DS, Becker-Cohen R, et al. (2010) Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 87: 392–399.
4. Beck BB, Baasner A, Buescher A, Habbig S, Reinitz N, et al. (2013) Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. European Journal of Human Genetics, 21: 162–172.
5. Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, et al. (2011) Primary hyperoxaluria type III gene HOGAL (formerly DHDPXL) as a possible risk factor for idiopathic calcium urolithiasis. Clin J Am Soc Nephrol 6: 2289–2295.
6. Van Woerden CS, Groothoff JW, Wanders RJ, Davin JC, Wijburg FA (2003) Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol Dial Transplant 18: 273–279.
7. Hoppe B, Langman C (2003) A United States survey on diagnosis, treatment and outcome of patients with primary hyperoxaluria. Pediatr Nephrol 18: 986–991.
8. Takayama T, Nagata M, Ichiyama A, Ozono S (2005) Primary hyperoxaluria type 1 in Japan. Am J Nephrol 25: 297–302. Erratum in: Am J Nephrol 2005; 25: 416.
9. Kopp N, Leumann E, (1995) Changing pattern of primary hyperoxaluria in Switzerland. Nephrol Dial Transplant 0: 2224–2227.
10. Hoppe B, Latta K, von Schneckenburg G, Kemper MJ, et al. (2005) Primary hyperoxaluria: the German experience. Am J Nephrol 25: 276–281.
11. Lieseg JC, Monico CG, Holmes WS, Bergstrahl EJ, Slezak JM, et al. (2005) International Registry for primary hyperoxaluria and Dent’s disease. Am J Nephrol 25: 290–96.
12. van Woerden C, Beck B, Huston S, Mandrile G (2010) The collaborative International Registry for primary hyperoxaluria and Dent’s disease. Pediatr Nephrol 25: 416.
13. Gargash T, Kheln N, Youssf G, Karouni W, Lakhoua MR, et al. (2012) Primary hyperoxaluria type 1 in Tunisian children. Saudi J Kidney Dis Transpl 23: 385–389.
14. Hoppe B. (2012) An update on primary hyperoxaluria Nat Rev Nephrol 8: 467–475.
15. Cochon P, Liutkus A, Farque S, Barmaison O, Ranchin B, et al. (2006) Primary hyperoxaluria type 1: still challenging! Pediatr Nephrol 21: 1075–1081.
16. Milliner DS, Eckhoit JT, Bergstrahl EJ, Wilson DM, Simah LH (1994) Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 331: 1533–1538.
17. Monico CG, Rossetti S, Olson JB, Milliner DS (2005) Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 67: 1704–1709.
18. Harambat J, Farque S, Aracavica C, Gagnagoud MF, Janssen F, et al. (2010) Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int 77: 443–449.
19. Van der Hoeven SM, van Woerden GS, Groothoff JW (2012) Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the dutch cohort. Nephrol Dial Transplant 27: 3835–3842.
20. Cochat P, Hilton SA, Aracavica C, Danpure CJ, Daoud M, et al. (2012) Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 27: 1729–1736.
21. Danpure M, Estepa L, Lacour B, Jungers P (1990) Unusual morphology of calcium oxalate crystals in primary hyperoxaluria. J Nephrolology 11: 31–55.
22. Daoud M, Jungers P, Bazin D (2008) Peculiar morphology of stones in primary hyperoxaluria. New Eng J Medicine 359: 100–102.
23. Fleisch H. (1978) Inhibitors and promoters of stone formation. Kidney Int 13: 361–371.
24. Hallouin PC, Rose GA, Sulaiman S (1982) Magnesium reduces calcium oxalate crystal formation in human whole urine. Clin Sci (Lond) 62: 17–19.
25. Kok DJ, Papapoulos, SE, Bijnovet, OLM. (1986) Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet 1: 1036–1038.
26. Ryall RL, Harnett RM, Marshall VR (1981) The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium-oxalate crystals in vitro. Clinica Chim Acta 112: 349–356.
27. Tischler HG, Berg C, Fernander AM, Nicola MA (1995) Effects of citrate on the different phases of calcium oxalate crystallization. Scanning Microsc 7: 381–389.
28. Chan BMP, Vincent K, Lajoie GA, Goldberg HA, Grohe B, et al. (2012) On the catalysis of calcium oxalate dihydrate formation by osteopontin peptides. Colloids and Surfaces B: Biointerfaces 96: 22–28.
29. Grohe B, Rogers KA, Goldberg HA, Hunter GK (2006) Crystallization kinetics of calcium oxalate hydrates studied by scanning confocal interference microscopy. J Crystal Growth 295: 148–157.
30. Grohe B, Rogers KA, Goldberg HA, Hunter GK (2006) Crystallography of calcium oxalate hydrates studied by scanning confocal interference microscopy. J Crystal Growth 295: 148–157.
31. Puttas A (2002) Mineral replacement reactions: from macroscopic observations to microscopic mechanisms. Min Magazine 66: 689–708.
32. Ouyr R, Nordkin BGC (1967) Urinary crystals and their relation to stone formation. Nature 215: 751–752.
33. Lepage I, Tawashi R (1981) Growth and characterization of calcium-oxalate dihydrate crystals (wedgelet). J Pharmacuet Sci 71: 1059–1062.
36. Tomazic BB, Sheehan ME, Nancollas GH (1992) Influence of natural and synthetic inhibitors on the crystallization of calcium oxalate hydrates. World J Urol 10: 216–225.
37. Tomazic BB, Nancollas GH (1980) The kinetics of dissolution of calcium-oxalate hydrates 2. The dihydrate. Investigative Urology 18, 97–101.
38. Ryall RL, Chauvet MC, Grover PK (2003) Intracrystalline proteins and urolithiasis: a comparison of the protein content and ultrastructure of urinary calcium oxalate monohydrate and dihydrate crystals. BJU International 96: 634–663.
39. Brčević LJ, Škrtić D, Garside J (1986) Transformation of calcium oxalate hydrates. J Crystal Growth 74: 309–400.
40. Grohe B, Chan BPH, Sørensen ES, Lajoie G, Goldberg HA, et al. (2011) Cooperation of phosphates and carboxylates controls calcium oxalate crystallization in ultrafiltered urine. Urol Res 39: 327–338.
41. Pedroza CE, Chien YC, Mckee MD (2008) Calcium oxalate crystals in fetal bovine serum: Implications for cell culture, phagocytosis and bionineralization studies in vitro. J Cellular Biochem 103: 1378–1393.
42. Hoppe B (2012) The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type III. Nephrol Dialysis Transplant 27: 3024–3026.
43. Elliot JS, Rabinowitz IN (1980) Calcium oxalate crystalluria: Crystal size in urine. J Urol 123: 324–327.
44. Coe FL, Evan AP, Worcester EM, Lingeman JE (2010) Three pathways for human kidney stone formation. Urol Res 8: 147–160.
45. Daudon M, Protat MF, Reveillaud RJ, Jaeschke-Boyer H (1983) Infrared spectrometry and Raman microprobe in the analysis of urinary calculi. Kidney Int 23: 442–450.